60d FRN - published 2024

Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Notices
(Authority: Government in the Sunshine
Act, 5 U.S.C. 552b)
Vicktoria J. Allen,
Deputy Secretary of the Commission.
[FR Doc. 2024–25018 Filed 10–23–24; 4:15 pm]
BILLING CODE 6715–01–P

FEDERAL RESERVE SYSTEM

ddrumheller on DSK120RN23PROD with NOTICES1

Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
Comments received are subject to
public disclosure. In general, comments
received will be made available without
change and will not be modified to
remove personal or business
information including confidential,
contact, or other identifying
information. Comments should not
include any information such as
confidential information that would not
be appropriate for public disclosure.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than November 12, 2024.
A. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690–1414.
Comments can also be sent
electronically to
Comments.applications@chi.frb.org:
1. The Deborah A. Talen Trust,
Deborah A. Talen, as trustee, both of

VerDate Sep<11>2014

17:40 Oct 24, 2024

Jkt 265001

Minneapolis, Minnesota; to become a
member of the Talen Family Control
Group, a group acting in concert, to
acquire voting shares of Talen, Inc., and
thereby indirectly acquire voting shares
of Farmers Savings Bank & Trust, both
of Traer, Iowa.
B. Federal Reserve Bank of San
Francisco (Joseph Cuenco, Assistant
Vice President, Formations &
Transactions) 101 Market Street, San
Francisco, California 94105. Comments
can also be sent electronically to
sf.fisc.comments.applications@
sf.frb.org:
1. Russell S. Colombo, Walla Walla,
Washington; to join Megan F. Clubb and
Clifford W. Kontos, both of Walla Walla,
Washington, a group acting in concert,
to control voting shares of Baker Boyer
Bancorp, and thereby indirectly control
voting shares of Baker Boyer National
Bank, both of Walla Walla, Washington.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Associate Secretary of the Board.
[FR Doc. 2024–24898 Filed 10–24–24; 8:45 am]

FEDERAL TRADE COMMISSION
Senior Executive Service Performance
Review Board
Federal Trade Commission

(FTC).
ACTION:

Notice.

Notice is hereby given of the
appointment of members to the FTC
Performance Review Board.
FOR FURTHER INFORMATION CONTACT:
Tamika Williams, Acting Chief Human
Capital Officer, 600 Pennsylvania
Avenue NW, Washington, DC 20580,
(202) 326–2184.
SUPPLEMENTARY INFORMATION:
Publication of the Performance Review
Board (PRB) membership is required by
5 U.S.C. 4314(c)(4). The PRB reviews
and evaluates the initial appraisal of a
senior executive’s performance by the
supervisor, and makes
recommendations regarding
performance ratings, performance
awards, and pay-for-performance pay
adjustments to the Chair.
The following individuals have been
designated to serve on the Commission’s
Performance Review Board:
Monique Fortenberry, Director, Office of
Workplace Inclusivity & Opportunity
Robin Moore, Principal Deputy General
Counsel
Maribeth Petrizzi, Assistant Director for
Compliance, Bureau of Competition
SUMMARY:

PO 00000

Frm 00078

David Robbins, Executive Director, PRB
Chair
Ted Rosenbaum, Deputy Director for
Research and Management, Bureau of
Economics
Rebecca Unruh, Deputy Director,
Bureau of Consumer Protection
Tamika Williams, Acting Chief Human
Capital Officer
By direction of the Commission.
April J. Tabor,
Secretary.
[FR Doc. 2024–24904 Filed 10–24–24; 8:45 am]
BILLING CODE 6750–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–25–0612; Docket No. CDC–2024–
0083]

Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

BILLING CODE P

AGENCY:

85213

Fmt 4703

Sfmt 4703

The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a continuing information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Well-Integrated
Screening and Evaluation for Women
Across the Nation (WISEWOMAN)
Reporting System. The WISEWOMAN
program is designed to prevent, detect,
and control, hypertension and other
cardiovascular disease (CVD) risk
factors through services such as health
coaching, and evidence informed
lifestyle programs, which are tailored
for individual and group behavior
change.

SUMMARY:

CDC must receive written
comments on or before December 24,
2024.

DATES:

You may submit comments,
identified by Docket No. CDC–2024–
0083 by of either the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for

ADDRESSES:

E:\FR\FM\25OCN1.SGM

25OCN1

85214

Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Notices

Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov )or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7118; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;

3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Well-Integrated Screening and
Evaluation for Women Across the
Nation (WISEWOMAN) Reporting
System (OMB Control No. 0920–0612,
Exp. 3/31/2025)—Revision—National
Center for Chronic Disease and
Prevention and Health Promotion
(NCCDPHP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The Well-Integrated Screening and
Evaluation for Women Across the
Nation (WISEWOMAN) program
sponsored by the CDC, provides services
to low income, uninsured, or
underinsured women aged 35–64. The
WISEWOMAN program is designed to
prevent, detect, and control
hypertension and other cardiovascular
disease (CVD) risk factors through
healthy behavior support services which
are tailored for individual and group
behavior change. The WISEWOMAN
program provides services to
participants who are jointly enrolled in
the National Breast and Cervical Cancer
Early Detection Program (NBCCEDP),
which is also administered by CDC.
The WISEWOMAN program is
administered by state health
departments and tribal programs. In
2023, a new five-year cooperative
agreement was awarded under Funding
Opportunity Announcement DP23–
0003, subject to the availability of funds.
CDC collects two types of information
from WISEWOMAN awardees. The
WISEWOMAN awardee submits an
electronic data file to CDC twice per
year. The Minimum Data Elements

(MDE) file contains data using a unique
identifier with client-level information
about CVD risk factors and types of
healthy behavior support services for
participants served by the program. The
estimated burden per response for the
MDE file is 25 hours. The Annual
Progress Report provides a narrative
summary of each awardee’s objectives
and the activities undertaken to meet
program goals. The estimated burden
per response is 16 hours.
The WISEWOMAN Program is
requesting three additional years to
continue data collection. The 2024 OMB
Directive 15 for a combined race and
ethnicity question will replace the
separate race and ethnicity minimum
data elements. Two MDEs are being
deleted and two MDEs are being added,
and a response option is being added to
one MDE. There are no changes to
overall burden. CDC will continue to
use the information collected from
WISEWOMAN awardees to support
program monitoring and improvement
activities, program assessment, and
evaluation of program outcomes. The
overall program evaluation helps to
demonstrate program accomplishments
and strengthen the evidence for strategy
implementation for improved
engagement of underserved populations.
It can also determine whether the
identified strategies and associated
activities can be implemented at various
levels within a state or tribal
organization. The data collection is
designed to demonstrate how
WISEWOMAN can obtain CVD health
outcome data on at-risk populations,
promote public education about CVD
risk-factors, and improve the availability
of healthy behavior support services for
under-served participants.
This is a Revision for the
WISEWOMAN information collection
(OMB Control No. 0920–0612, Exp. 03/
31/2025). Participation in this
information collection is required as a
condition of cooperative agreement
funding. There are no costs to
respondents other than their time. The
total estimated annual burden hours are
2,640.

ddrumheller on DSK120RN23PROD with NOTICES1

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Number of
responses per
respondent

Average
burden per
response
(in hrs.)

Total
burden
(in hrs.)

Type of respondents

Form name

WISEWOMAN Awardees ...........

Screening and Assessment and Lifestyle Program MDEs .............
Annual Progress Report ..................................................................

40
40

2
1

25
16

2,000
640

Total .....................................

..........................................................................................................

......................

..........................

....................

2,640

VerDate Sep<11>2014

17:40 Oct 24, 2024

Jkt 265001

PO 00000

Frm 00079

Fmt 4703

Sfmt 4703

E:\FR\FM\25OCN1.SGM

25OCN1

Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2024–24921 Filed 10–24–24; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–25–1385; Docket No. CDC–2024–
0084]

Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a continuing information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Characteristics
of Cases of Priority Fungal Diseases.
These case report forms (CRF) collect
information on patient demographics,
underlying conditions, diagnosis,
treatments, healthcare utilization, and
outcomes of patients with
coccidioidomycosis, histoplasmosis,
blastomycosis, Candida auris, triazoleresistant Aspergillus fumigatus infection
or colonization, or antifungal-resistant
dermatophytosis, chromoblastomycosis,
mycetoma, and sporotrichosis.
DATES: CDC must receive written
comments on or before December 24,
2024.
SUMMARY:

You may submit comments,
identified by Docket No. CDC–2024–
0084 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.

ddrumheller on DSK120RN23PROD with NOTICES1

ADDRESSES:

VerDate Sep<11>2014

17:40 Oct 24, 2024

Jkt 265001

Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Characteristics of Cases of Priority
Fungal Diseases (OMB Control No.
0920–1385, Exp. 4/30/2027)—
Revision—National Center for Emerging
and Zoonotic Infectious Diseases

PO 00000

Frm 00080

Fmt 4703

Sfmt 4703

85215

(NCEZID), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
Fungal diseases cause substantial
illness, ranging from mild infection to
severe or life-threatening invasive
disease. They also constitute a
considerable financial burden on
patients and healthcare systems.
Awareness of fungal diseases is low,
and data collection has historically been
limited in size, scope, and coordination,
which has hindered our understanding
of these diseases. Detailed
epidemiologic and clinical data are
critical to inform appropriate public
health responses.
CDC plans to enhance surveillance of
high priority fungal diseases across the
United States to better characterize
factors such as disease burden,
geographic scope, patient risk factors,
health disparities, healthcare utilization,
outcomes, and emerging trends. This
project will serve as a Revision to the
information collection project
Characteristics of Cases of Priority
Fungal Diseases (OMB Control No.
0920–1385). The Revision will expand
the number of fungal diseases for which
data may be collected. In addition to
triazole-resistant A. fumigatus
infections, coccidioidomycosis,
histoplasmosis, blastomycosis, C. auris,
and antifungal-resistant
dermatophytosis, Case Report Forms
(CRF) have also been developed for
chromoblastomycosis, mycetoma, and
sporotrichosis.
CDC plans to use standardized CRFs
to collect public health surveillance
data for cases of these diseases regarding
demographics (e.g., age, sex, race/
ethnicity, location of residence),
underlying medical conditions,
diagnosis (e.g., clinical presentation,
laboratory testing), treatments, and
outcomes (e.g., hospitalization, vital
status). The corresponding CRF would
be filled out voluntarily by state, local
or tribal health departments, federal
agencies, and members of the private
sector (e.g., academic institutions), and
contains a section for medical chart
review and an optional supplemental
interview (including data on potential
occupational or environmental
exposures) of the patient or their
representative. Findings can help
identify populations at higher risk of
these diseases, detect emerging
epidemiologic trends, and guide
prevention and response efforts. They
can also help better focus public and
healthcare provider outreach, inform
efforts to contain or mitigate spread, and
influence health policy and research on
prevention and treatment.

E:\FR\FM\25OCN1.SGM

25OCN1